HKG:1873

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.